Inositol polyphosphate derivatives and methods of using same

Details Inositol polyphosphate derivatives and methods of using same Inositol polyphosphate derivatives and methods of using same

1997-09-19

1999-11-02

Weddington, Kevin E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514851, A61K 3170

Patent

active

059770783

ABSTRACT:
The present invention provides compositions that are cell permeable antagonists of inositol polyphosphates. In addition, the invention provides methods for enhancing chloride ion secretion from a cell by contacting the cells with cell permeable antagonists of inositol polyphosphates. The invention also provides methods for enhancing chloride ion secretion in an individual by administering cell permeable antagonists of inositol polyphosphates to the individual. The invention additionally provides methods for alleviating a sign or symptom associated with cystic fibrosis in an individual by administering a cell permeable antagonist of inositol polyphosphates to the individual. The invention also provides compositions that are cell permeable agonists of inositol polyphosphates. In addition, the invention provides methods for decreasing chloride ion secretion from a cell by contacting the cell with cell permeable agonists of inositol polyphosphates. The invention also provides methods for decreasing chloride ion secretion in an individual by administering cell permeable agonists of inositol polyphosphates to the individual. The invention additionally provides methods for alleviating a sign or symptom associated with secretory diarrhea in an individual by administering cell permeable agonists of inositol polyphosphates to the individual.

REFERENCES:
patent: 5693521 (1997-12-01), Tsien et al.
Berger et al., "Therapeutical Efficacy of a Novel Chloride Transport Blocker and an IP.sub.3 -Analogue in Vasogenic Brain Edema," Acta Neurochir Supp. 60:534-537 (1994).
Ho et al., "Ins(3,4,5,6)P.sub.4 specifically inhibits a receptor-mediated Ca.sup.2+ -dependent Cl.sup.- current in CFPAC-1 cells," Am. J. Physiol. 272:C1160-C1168 (1997).
Ismailov et al., "A biologic function for an "orphan" messenger: D-myo-Inositol 3,4,5,6-tetrakisphosphate selectively blocks epithelial calcium-activated chloride channels," Proc. Natl. Acad. Sci USA 93:10505-10509 (1996).
Kachintorn et al., "Elevation of inositol tetrakisphosphate parallels inhibition of Ca.sup.2+ -dependent C1.sup.- secretion in T84 cell," Am. J. Physiol. 264 (3 Pt 1):C671-C676 (1993).
Kruppa et al., "Bioactivatable derivatives of 8-Substituted cAMP-analogues," Bioorganic & Medicinal Chemistry Letters 7(7):945-948 (1997).
Li et al., "Membrane-permeant esters of inositol polyphosphates, chemical syntheses and biological applications," Tetrahedron 53(35):12017-12040 (1997).
Roemer et al., "Synthesis of D-myo-Inositol 3,4,5,6-and 1,4,5,6-Tetrakisphosphate Analogues and their Membrane-permeant Derivatives," J. Chem. Soc., Chem. Commun. N4:411-412 (1995).
Roemer et al., "Membrane-permeant analogues of the putative second messenger myo-inositol 3,4,5,6-tetrakisphosphate," J. Chem. Soc., Perkin Trans. 1 N14:1683-1694 (1996).
Schultz et al., "Membrane-permeant derivatives of cyclic AMP optimized for high potency, prolonged activity, or rapid reversibility," Molecular Pharmacology 46:702-708 (1994).
Schultz et al., "Acetoxymethyl esters of phosphates, enhancement of the permeability and potency of cAMP," J. Biol. Chem. 268(9):6316-6322 (1993).
Staub et al., "Treatment of Vasogenic Brain Edema with the Novel Cl.sup.- Transport Inhibitor Torasemide," J. of Neurotrauma 11(6):679-690 (1994).
Tan et al., "Properties of the Inositol 3,4,5,6-tetrakisphosphate 1-Kinase Purified from Rat Liver," J. Biol. Chem. 272(4):2285-2290 (1997).
Uribe et al., "Phosphatidylinositol 3-Kinase Mediates the Inhibitory Effect of Epidermal Growth Factor on Calcium-dependent Chloride Secretion," J. Biol. Chem. 271(43):26588-26595 (1996).
Uribe et al., "Epidermal growth factor inhibits Ca.sup.2+ -dependent Cl.sup.- transport in T84 human colonic epithelial cells," Am. J. Physiol. 271(3 Pt 1):C914-C922 (1996).
Vajanaphanich et al., "Long-term uncoupling of chloride secretion from intracellular calcium levels by Ins(3,4,5,6)P.sub.4," Nature 371:711-714 (1994).
Roemer et al., "Antagonists of the novel second messenger Ins(3,4,5,6)P.sub.4," Symposium on Hormones and Cell Regulation, Sep., 1996.
Schultz et al., "Membrane-permeant derivatives of inositol polyphosphates: effects on cytosolic Ca.sup.2+ and Ca.sup.2+ -regulated processes," Calcium Signaling: 20th Karolinska Institute Nobel Conference, Saltsjobaden, Sweden (1992).
Vajanaphanich et al., "Cross-talk between calcium and cAMP-dependent intracellular signaling pathways," J. Clin. Invest. 96:386-393 (1995).
Xie et al., "Inositol 3,4,5,6-Tetrakisphosphate Inhibits the Calmodulin-dependent Protein Kinase II-activated Chloride Conductance in T84 Colonic Epithelial Cells," J. Biol. Chem. 271(24):14092-14097 (1996).
Zhuo et al., "Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation," Nature 368:635-639 (1994).

Affiliated with

Also associated with

Rating

Inositol polyphosphate derivatives and methods of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inositol polyphosphate derivatives and methods of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inositol polyphosphate derivatives and methods of using same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2135551